SOTORASIB DOSING REGIMEN
Application
US20260083741A1
Kind: A1
Mar 26, 2026
Inventors
Brett E. Houk, Panli Cardona
Abstract
The present disclosure provides method of administering sotorasib to a patient, e.g., a patient with a cancer comprising a KRAS G12C mutation, wherein the patient is further in need of treatment with a breast cancer resistance protein (BCRP) substrate. e.g., rosuvastatin.
CPC Classifications
A61K 31/519
A61K 31/505
Filing Date
2022-12-16
Application No.
19112616